Early survival in patients who completed the MCS therapy, defined as discharge, amounted to 63.6% (n = 7). No malfunctions of the MCS system were reported. The most frequent complications following the therapy were: cardiac tamponade or bleeding requiring an intervention - 25% (n = 3), renal failure requiring dialysis - 25% (n = 3), ischaemic stroke associated with the MCS - 16.6% (n = 2), bacteraemia - 16.6% (n = 2), and wound infection - 8% (n = 1). Survival until transplantation or explantation was 91.67%. OpenOffice Calc spreadsheet was used for data analysis.Īverage MCS time was 41 days ± 25 (from 15 to 91 days). The presented data was retrospectively obtained from the CliniNET system of the Institute of Cardiology. Episodes of cardiac arrest were reported in three patients three other patients experienced serious arrhythmias, which accelerated the decision to implant MCS. Four of the analysed patients (33%) required prior circulatory support with other devices: IABP (n = 2) or ECMO (n = 2). Full-blown cardiogenic shock was observed in all patients before MCS implantation. The POLCAS system was implanted in 12 patients aged 16-63 years (42 ± 17 years) during a period of 12 months (from January to December, 2014). The aim of the study was an evaluation of the results of treatment utilising the POLCAS MCS system at our institution in 2014. The MCS presented in this study is associated with a significant risk of complications and its use is increasingly considered controversial. Currently, it is being widely replaced by continuous-flow mechanical circulatory support equipment of the second and third generations (HeartMateII, HeartWare). The POLCAS pulsatile-flow system has been used in our institution for 15 years. Mechanical circulatory support (MCS) is a recognised method of treatment for patients with end-stage chronic or acute heart failure.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |